CytoSorbents Teams With INTENSIVMED for CytoSorb(R) Distribution in Russia

CytoSorbents Teams With INTENSIVMED for CytoSorb(R) Distribution in Russia 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 11/12/13 --  CytoSorbents
Corporation (OTCQB: CTSO), a critical care focused therapeutic device
company using blood purification to treat life-threatening illnesses,
announced distribution of its CytoSorb(R) extracorporeal cytokine
filter in Russia through an exclusive distribution agreement with
INTENSIVMED, LLC based out of Moscow, Russia. This multi-year
agreement is subject to annual minimum guaranteed orders of
CytoSorb(R) to maintain exclusivity.  
Mr. Victor Gorobets, CEO of INTENSIVMED LLC stated, "We see a big
future for CytoSorb(R) in Russia as well as all over the world. The
CytoSorb(R) technology offers potential rescue to the most needy of
recipients -- the critically ill -- and that is a major victory in
the modern medical world. All the most challenging conditions --
sepsis, organ failure, massive cytokine storm and many others could
be successfully treated with it. This breakthrough technology brings
healthcare standards to a new level and we are happy and excited to
become part of it." 
Dr. Phillip Chan, CEO of CytoSorbents Corporation commented, "Russia
represents a tremendous market opportunity for CytoSorb(R) outside of
the European Union. INTENSIVMED's status as a well-established
critical care medical device distributor that also distributes
heart-lung machines for a leading cardiac surgery device company in
Russia, makes them a natural choice to distribute CytoSorb(R). We are
delighted to be working with INTENSIVMED and look forward to a
fruitful collaboration. " 
Russia is the largest country in the world in terms of land. Its
gross domestic product of $2 trillion makes it the 8th largest
economy in the world, driven by a wealth of natural resources
including oil, natural gas, coal, timber and minerals. The top 10
cities, including the capital city of Moscow and St. Petersburg, are
home to nearly 20% of the country's total population of 145 million.
According to the World Health Organization, Russia spends
approximately 6% of its GDP (2011), or approximately $125 billion, on
healthcare annually. The average life expectancy of its citizens is
63 years of age for men, and 75 years of age for women.  
CytoSorb(R) is the only specifically approved extracorporeal cytokine
filter commercially available throughout all 28 countries of the
European Union and in countries that accept CE Mark approval. It is
currently being sold directly in Germany, Austria and Switzerland,
with expanding distribution in the United Kingdom, Ireland, the
Netherlands, Turkey, India, and Russia. 
About INTENSIVMED
 INTENSIVMED LLC is an established supplier of
medical equipment and disposables to the Russian public and private
healthcare institutions and is headquartered in Moscow and St.
Petersburg, Russia. Its business focus is intensive care line
products and its main customers are Anesthesiology, Reanimatology and
Intensive Care Units, cardiac surgery operating theaters, and blood
transfusion departments. One of the company's main aims is to
introduce innovation into doctors' everyday routine, and thus
INTENSIVMED is the golden sponsor of the school in AR and ICU
post-graduate training. For more information, please visit:
www.intensivmed.ru 
About CytoSorbents Corporation
 CytoSorbents Corporation is a
critical care focused therapeutic device company using blood
purification to modulate the immune system and fight multi-organ
failure in life-threatening illnesses. Its purification technology is
based on biocompatible, highly porous polymer beads that can actively
remove toxic substances from blood and other bodily fluids by pore
capture and adsorption. CytoSorb(R), the Company's flagship product,
is approved in the European Union as a safe and effective
extracorporeal cytokine filter, designed to reduce the "cytokine
storm" that could otherwise cause massive inflammation, organ failure
and death in common critical illnesses such as sepsis, burn injury,
trauma, lung injury, and pancreatitis. These are conditions where the
mortality is extremely high, yet no effective treatments exist.
Additional information is available for download on the Company's
website: http://www.cytosorbents.com. 
Forward-Looking Statements
 This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press release
are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking statements.
Actual results may differ materially from those expressed or implied
by the statements herein. Risk factors are detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at
http://www.sec.gov. 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
asheinwald@allianceadvisors.net 
Valter Pinto
(914) 669-0222 x201
valter@allianceadvisors.net 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378
jabraham@jqapartners.com 
 
 
Press spacebar to pause and continue. Press esc to stop.